$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000161521918000052 Filed on August 01, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$469.1K	$245.5K	$335.5K
YoY Change	13.41%	-26.83%	197.75%
Cost Of Revenue	$91.94K	$179.9K	$145.3K
YoY Change	-38.2%	23.82%	31.0%
Gross Profit	$377.1K	$65.56K	$190.2K
YoY Change	42.39%	-65.53%	10743.67%
Gross Profit Margin	80.4%	26.7%	56.69%
Selling, General & Admin	$1.880M	$2.780M	$4.990M
YoY Change	-61.87%	-44.29%	-7.25%
% of Gross Profit	498.52%	4240.58%	2623.58%
Research & Development	$353.6K	$6.175M	$4.076M
YoY Change	-92.54%	51.48%	-33.12%
% of Gross Profit	93.77%	9418.66%	2143.15%
Depreciation & Amortization	$60.00K	$60.00K	$80.00K
YoY Change	-25.0%	-25.0%	33.33%
% of Gross Profit	15.91%	91.52%	42.06%
Operating Expenses	$782.6K	$9.349M	$9.212M
YoY Change	-92.03%	1.48%	-20.47%
Operating Profit	-$313.5K	-$9.104M	-$8.877M
YoY Change	-96.67%	2.55%	-22.61%
Interest Expense	$6.064K	$50.00K	$70.00K
YoY Change	-92.42%	-28.57%	-36.36%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.640M	-$9.050M	-$8.800M
YoY Change	-71.7%	2.84%	-23.28%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$307.5K	$111.2K	-$8.805M
YoY Change	-96.71%	-101.26%	-22.52%
Net Earnings / Revenue	-65.55%	45.31%	-2624.15%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.667M	-$12.57M	-$12.75M
COMMON SHARES
Basic Shares Outstanding	18.07M shares	18.01M shares	17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.00M	$15.80M	$47.10M
YoY Change	-66.58%	-66.45%	-37.12%
Cash & Equivalents	$12.96M	$15.76M	$39.25M
Short-Term Investments	$0.00	$0.00	$8.000M
Other Short-Term Assets	$500.0K	$900.0K	$1.200M
YoY Change	-54.55%	-25.0%	-47.83%
Inventory	$223.5K	$275.7K	$688.2K
Prepaid Expenses
Receivables	$20.99K	$17.33K	$34.74K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.68M	$16.91M	$49.06M
YoY Change	-66.26%	-65.54%	-36.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$127.1K	$180.0K	$448.1K
YoY Change	-68.31%	-59.82%	-29.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$253.7K	$306.6K	$574.7K
YoY Change	-61.22%	-46.64%	-30.65%
TOTAL ASSETS
Total Short-Term Assets	$13.68M	$16.91M	$49.06M
Total Long-Term Assets	$253.7K	$306.6K	$574.7K
Total Assets	$13.94M	$17.21M	$49.63M
YoY Change	-66.18%	-65.32%	-36.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.279M	$1.145M	$1.806M
YoY Change	39.2%	-36.59%	16.93%
Accrued Expenses	$1.600M	$2.600M	$3.100M
YoY Change	-58.97%	-16.13%	82.35%
Deferred Revenue	$0.00	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.888M	$3.793M	$5.033M
YoY Change	-41.92%	-24.65%	48.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.888M	$3.793M	$5.033M
Total Long-Term Liabilities	$0.00	$0.00	$100.0K
Total Liabilities	$2.888M	$3.803M	$5.125M
YoY Change	-42.55%	-25.81%	50.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$131.0M	-$128.3M	-$93.72M
YoY Change	27.08%	36.91%	61.28%
Common Stock	$1.807K	$1.807K	$1.729K
YoY Change	3.02%	4.51%	6.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.488M	-$1.184M	$44.50M
YoY Change
Total Liabilities & Shareholders Equity	$13.94M	$17.21M	$49.63M
YoY Change	-66.18%	-65.32%	-36.56%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$307.5K	$111.2K	-$8.805M
YoY Change	-96.71%	-101.26%	-22.52%
Depreciation, Depletion And Amortization	$60.00K	$60.00K	$80.00K
YoY Change	-25.0%	-25.0%	33.33%
Cash From Operating Activities	-$2.790M	-$8.260M	-$5.690M
YoY Change	-65.34%	45.17%	-39.01%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$30.00K
YoY Change	-100.0%	-100.0%	-83.33%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.000M	$23.78M
YoY Change	-100.0%	-91.59%	-528.47%
Cash From Investing Activities	$0.00	$2.000M	$23.74M
YoY Change	-100.0%	-91.58%	-514.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	70.00K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-2.790M	-8.260M	-5.690M
Cash From Investing Activities	0.000	2.000M	23.74M
Cash From Financing Activities	0.000	70.00K	0.000
Net Change In Cash	-2.790M	-6.190M	18.05M
YoY Change	-85.19%	-134.29%	-219.85%
FREE CASH FLOW
Cash From Operating Activities	-$2.790M	-$8.260M	-$5.690M
Capital Expenditures	$0.00	$0.00	-$30.00K
Free Cash Flow	-$2.790M	-$8.260M	-$5.660M
YoY Change	-65.13%	45.94%	-38.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19630	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9585659	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	601646	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-859107	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22554	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	184	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	101705	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-29410	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-207063	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-139206	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	283209	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	93909	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	150196	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-22274	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	369483	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9607390	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1997751	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53741	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18069476	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Flex Pharma, Inc.
CY2017Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3712221	USD
CY2018Q2	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2588596	USD
CY2017Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1850115	USD
CY2018Q2	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1400000	USD
CY2018Q2	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1402929	USD
CY2017Q4	flks	Accrued Research And Development Expense Other Current AccruedResearchAndDevelopmentExpenseOtherCurrent	652285	USD
CY2018Q2	flks	Accrued Research And Development Expense Other Current AccruedResearchAndDevelopmentExpenseOtherCurrent	146895	USD
CY2018Q2	flks	Cash Retention Bonuses Payable CashRetentionBonusesPayable	1210000	USD
CY2018Q2	flks	Cash Retention Bonuses Payable Upon Changein Control CashRetentionBonusesPayableUponChangeinControl	500000	USD
CY2018Q2	flks	Cash Retention Bonuses Payable Upon Employeesin Good Standing CashRetentionBonusesPayableUponEmployeesinGoodStanding	710000	USD
	flks	Common Stock Numberof Votes CommonStockNumberofVotes	1	vote
	flks	Contractwith Customer Refund Period ContractwithCustomerRefundPeriod	P30D
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-64800	USD
CY2018Q2	flks	Contractwith Customer Refund Period ContractwithCustomerRefundPeriod	P14D
CY2017Q4	flks	Debt Securities Availableforsale Significant Unrealized Loss Position Numberof Positions DebtSecuritiesAvailableforsaleSignificantUnrealizedLossPositionNumberofPositions	0	security
	flks	Inventory Purchasesin Accounts Payableand Accrued Expense InventoryPurchasesinAccountsPayableandAccruedExpense	441116	USD
	flks	Inventory Purchasesin Accounts Payableand Accrued Expense InventoryPurchasesinAccountsPayableandAccruedExpense	0	USD
CY2018Q2	flks	Numberof Retained Employees NumberofRetainedEmployees	7	employee
CY2018Q2	flks	Percentage Decreasein Company Workforce PercentageDecreaseinCompanyWorkforce	-0.60
	flks	Percentage Decreasein Company Workforce PercentageDecreaseinCompanyWorkforce	-0.60
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	7100	USD
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	0	USD
CY2017Q2	flks	Sales Discounts SalesDiscounts	74000	USD
	flks	Sales Discounts SalesDiscounts	120000	USD
CY2018Q2	flks	Sales Discounts SalesDiscounts	9000	USD
	flks	Sales Discounts SalesDiscounts	17000	USD
CY2018Q2	flks	Severance Benefits Payable Upon Changein Controland Termination Without Cause SeveranceBenefitsPayableUponChangeinControlandTerminationWithoutCause	1125000	USD
CY2018Q2	flks	Sharebased Compensation Arrangementby Sharebased Payment Award Numberof Employees Granted Options SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofEmployeesGrantedOptions	7	employee
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2004440	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1145333	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10385	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17329	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	107595	USD
CY2018Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	18834	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	227980	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	157262	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1247	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140184630	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141722546	USD
CY2017Q2	us-gaap	Advertising Expense AdvertisingExpense	1250000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1915000	USD
CY2018Q2	us-gaap	Advertising Expense AdvertisingExpense	264000	USD
	us-gaap	Advertising Expense AdvertisingExpense	772000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1073346	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2262098	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	510993	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1419933	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3354077	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3102147	shares
CY2017Q4	us-gaap	Assets Assets	34992772	USD
CY2018Q2	us-gaap	Assets Assets	17212750	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	34535137	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	16906111	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	38	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1285	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14130970	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	14129723	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2017Q4	us-gaap	Cash Cash	19186036	USD
CY2018Q2	us-gaap	Cash Cash	15756971	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15756971	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22542635	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39253396	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19312631	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15883566	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16710761	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3429065	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17972166	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18069476	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17797178	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18066142	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1780	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	1807	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8797886	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17077020	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9051965	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17273852	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	72188	USD
CY2018Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	145325	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	224431	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	179945	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	263879	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	8191315	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	6	security
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	58821	USD
CY2018Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	58821	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	39214	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9804	USD
	us-gaap	Depreciation Depreciation	171109	USD
	us-gaap	Depreciation Depreciation	124000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	874246	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	313794	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M21D
CY2018Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2982000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4990943	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2994649	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6691936	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1127164	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8323	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	62385	USD
CY2017Q2	us-gaap	Interest Income Operating InterestIncomeOperating	72342	USD
CY2018Q2	us-gaap	Interest Income Operating InterestIncomeOperating	51809	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	111402	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	431891	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	275693	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17411	USD
CY2018Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7240	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	414480	USD
CY2018Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	268453	USD
CY2017Q2	us-gaap	Inventory Write Down InventoryWriteDown	17800	USD
	us-gaap	Inventory Write Down InventoryWriteDown	17800	USD
CY2018Q2	us-gaap	Inventory Write Down InventoryWriteDown	85000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	85000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	15895	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-11537	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5886884	USD
CY2018Q2	us-gaap	Liabilities Liabilities	3802554	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34992772	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17212750	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5847670	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3792750	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14129723	USD
CY2018Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2047	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118010	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30624261	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14120848	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13915547	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17667923	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8804623	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17073018	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-9051872	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17275099	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8804623	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17073018	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9051872	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17275099	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	9212488	USD
	us-gaap	Operating Expenses OperatingExpenses	17801284	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	9349183	USD
	us-gaap	Operating Expenses OperatingExpenses	17810585	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8876965	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17223214	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9103681	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17386501	USD
CY2017Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6737	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4002	USD
CY2018Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-93	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1247	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	777102	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	856118	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	40282017	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16117184	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3375	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1415	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2047	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	118010	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	331040	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	180044	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4076220	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7991194	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6174589	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10854770	USD
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	126595	USD
CY2018Q2	us-gaap	Restricted Cash RestrictedCash	126595	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	918000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2018Q2	us-gaap	Restructuring Reserve RestructuringReserve	548882	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	548882	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111079275	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128314157	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	335523	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	578070	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245502	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	424084	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2262098	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1419933	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P48M
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1440107	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	230630	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	621282	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	654544	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1467544	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	803600	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42136	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2580491	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3098813	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.65
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.86
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	42136	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3098813	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.86
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.82
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.17
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.81
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	42136	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M27D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M6D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97310	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	29105888	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	13410196	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17130264	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17002597	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18037274	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17965989	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001615219-18-000052-index-headers.html	Edgar Link	pending
0001615219-18-000052-index.html	Edgar Link	pending
0001615219-18-000052.txt	Edgar Link	pending
0001615219-18-000052-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flex20180630ex-103.htm	Edgar Link	pending
flexpharmalogo002.jpg	Edgar Link	pending
flks-20180331.xml	Edgar Link	completed
flks-20180331.xsd	Edgar Link	pending
flks-20180331_cal.xml	Edgar Link	unprocessable
flks-20180331_def.xml	Edgar Link	unprocessable
flks-20180331_lab.xml	Edgar Link	unprocessable
flks-20180331_pre.xml	Edgar Link	unprocessable
flks2018063010-q.htm	Edgar Link	pending
flks20180630ex-101.htm	Edgar Link	pending
flks20180630ex-102.htm	Edgar Link	pending
flks20180630ex-104.htm	Edgar Link	pending
flks20180630ex-311.htm	Edgar Link	pending
flks20180630ex-312.htm	Edgar Link	pending
flks20180630ex-321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2018 Q3 Form 10-Q Financial Statement

#000161521918000052 Filed on August 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2018 Q3 Form 10-Q Financial Statement

#000161521918000052 Filed on August 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx